Tri-nasal triamcinolone acetonide nasal spray 200 and 400 μg qd versus placebo and nasacort triamcinolone acetonide nasal aerosol 440 μg qd in patients suffering from seasonal allergic rhinitis during the grass season

Richard R Rosenthal, W. Berger, E. Bronsky, R. Dockhorn, P. Korenblat, K. Lampl, W. Lumry, S. Pollard, G. Raphael, C. Rohr, G. Shapiro, Martin D. Valentine, A. Wanderer, L. Fleming, N. Lavallee, M. Stepanians, J. Karafilidis, J. Shilstone, Elliot Ellis

Research output: Contribution to journalArticle

Abstract

Tri-Nasal Nasal Spray is an investigational solution of triamcinolone acetonide (TAA) currently being evaluated as a treatment for allergic rhinitis. The safety and efficacy of 200 and 400 μg once daily doses of Tri- Nasal Nasal Spray, an active control (440 μg once daily of Nasacort Nasal aerosol), and Tri-Nasal Spray placebo were compared over a 2-week treatment period in a double-blind (the Nasacort treatment was not blinded), parallel design trial. A total of 377 adult patients in 13 centers were enrolled during the grass pollen season. The primary efficacy variable was the weekly average of the SSI (Symptom Severity Index), the sum of daily nasal congestion, rhinorrhea, and sneezing severity scores from the patient diary. A total of 355 patients completed the study. All active treatments were significantly more effective than placebo in relieving nasal symptoms at each treatment week. The 400 μg Tri-Nasal Nasal Spray and Nasacort treatments had a rapid onset of action, demonstrating significant improvement in the SSI versus placebo by the second day of treatment. Results for the individual nasal symptoms and other secondary efficacy measures paralleled those of the primary efficacy variables. Tri-Nasal Nasal Spray and Nasacort were comparable in safety, and in treating the nonocular symptoms of seasonal allergic rhinitis.

Original languageEnglish (US)
Pages (from-to)427-433
Number of pages7
JournalAmerican Journal of Rhinology
Volume12
Issue number6
StatePublished - 1998
Externally publishedYes

Fingerprint

Nasal Sprays
Triamcinolone Acetonide
Seasonal Allergic Rhinitis
Poaceae
Nose
Placebos
Therapeutics
Sneezing
Safety
Pollen

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Tri-nasal triamcinolone acetonide nasal spray 200 and 400 μg qd versus placebo and nasacort triamcinolone acetonide nasal aerosol 440 μg qd in patients suffering from seasonal allergic rhinitis during the grass season. / Rosenthal, Richard R; Berger, W.; Bronsky, E.; Dockhorn, R.; Korenblat, P.; Lampl, K.; Lumry, W.; Pollard, S.; Raphael, G.; Rohr, C.; Shapiro, G.; Valentine, Martin D.; Wanderer, A.; Fleming, L.; Lavallee, N.; Stepanians, M.; Karafilidis, J.; Shilstone, J.; Ellis, Elliot.

In: American Journal of Rhinology, Vol. 12, No. 6, 1998, p. 427-433.

Research output: Contribution to journalArticle

Rosenthal, RR, Berger, W, Bronsky, E, Dockhorn, R, Korenblat, P, Lampl, K, Lumry, W, Pollard, S, Raphael, G, Rohr, C, Shapiro, G, Valentine, MD, Wanderer, A, Fleming, L, Lavallee, N, Stepanians, M, Karafilidis, J, Shilstone, J & Ellis, E 1998, 'Tri-nasal triamcinolone acetonide nasal spray 200 and 400 μg qd versus placebo and nasacort triamcinolone acetonide nasal aerosol 440 μg qd in patients suffering from seasonal allergic rhinitis during the grass season', American Journal of Rhinology, vol. 12, no. 6, pp. 427-433.
Rosenthal, Richard R ; Berger, W. ; Bronsky, E. ; Dockhorn, R. ; Korenblat, P. ; Lampl, K. ; Lumry, W. ; Pollard, S. ; Raphael, G. ; Rohr, C. ; Shapiro, G. ; Valentine, Martin D. ; Wanderer, A. ; Fleming, L. ; Lavallee, N. ; Stepanians, M. ; Karafilidis, J. ; Shilstone, J. ; Ellis, Elliot. / Tri-nasal triamcinolone acetonide nasal spray 200 and 400 μg qd versus placebo and nasacort triamcinolone acetonide nasal aerosol 440 μg qd in patients suffering from seasonal allergic rhinitis during the grass season. In: American Journal of Rhinology. 1998 ; Vol. 12, No. 6. pp. 427-433.
@article{ed18de489e1341b5a4e6861ec7b01dc5,
title = "Tri-nasal triamcinolone acetonide nasal spray 200 and 400 μg qd versus placebo and nasacort triamcinolone acetonide nasal aerosol 440 μg qd in patients suffering from seasonal allergic rhinitis during the grass season",
abstract = "Tri-Nasal Nasal Spray is an investigational solution of triamcinolone acetonide (TAA) currently being evaluated as a treatment for allergic rhinitis. The safety and efficacy of 200 and 400 μg once daily doses of Tri- Nasal Nasal Spray, an active control (440 μg once daily of Nasacort Nasal aerosol), and Tri-Nasal Spray placebo were compared over a 2-week treatment period in a double-blind (the Nasacort treatment was not blinded), parallel design trial. A total of 377 adult patients in 13 centers were enrolled during the grass pollen season. The primary efficacy variable was the weekly average of the SSI (Symptom Severity Index), the sum of daily nasal congestion, rhinorrhea, and sneezing severity scores from the patient diary. A total of 355 patients completed the study. All active treatments were significantly more effective than placebo in relieving nasal symptoms at each treatment week. The 400 μg Tri-Nasal Nasal Spray and Nasacort treatments had a rapid onset of action, demonstrating significant improvement in the SSI versus placebo by the second day of treatment. Results for the individual nasal symptoms and other secondary efficacy measures paralleled those of the primary efficacy variables. Tri-Nasal Nasal Spray and Nasacort were comparable in safety, and in treating the nonocular symptoms of seasonal allergic rhinitis.",
author = "Rosenthal, {Richard R} and W. Berger and E. Bronsky and R. Dockhorn and P. Korenblat and K. Lampl and W. Lumry and S. Pollard and G. Raphael and C. Rohr and G. Shapiro and Valentine, {Martin D.} and A. Wanderer and L. Fleming and N. Lavallee and M. Stepanians and J. Karafilidis and J. Shilstone and Elliot Ellis",
year = "1998",
language = "English (US)",
volume = "12",
pages = "427--433",
journal = "American Journal of Rhinology and Allergy",
issn = "1945-8924",
publisher = "OceanSide Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Tri-nasal triamcinolone acetonide nasal spray 200 and 400 μg qd versus placebo and nasacort triamcinolone acetonide nasal aerosol 440 μg qd in patients suffering from seasonal allergic rhinitis during the grass season

AU - Rosenthal, Richard R

AU - Berger, W.

AU - Bronsky, E.

AU - Dockhorn, R.

AU - Korenblat, P.

AU - Lampl, K.

AU - Lumry, W.

AU - Pollard, S.

AU - Raphael, G.

AU - Rohr, C.

AU - Shapiro, G.

AU - Valentine, Martin D.

AU - Wanderer, A.

AU - Fleming, L.

AU - Lavallee, N.

AU - Stepanians, M.

AU - Karafilidis, J.

AU - Shilstone, J.

AU - Ellis, Elliot

PY - 1998

Y1 - 1998

N2 - Tri-Nasal Nasal Spray is an investigational solution of triamcinolone acetonide (TAA) currently being evaluated as a treatment for allergic rhinitis. The safety and efficacy of 200 and 400 μg once daily doses of Tri- Nasal Nasal Spray, an active control (440 μg once daily of Nasacort Nasal aerosol), and Tri-Nasal Spray placebo were compared over a 2-week treatment period in a double-blind (the Nasacort treatment was not blinded), parallel design trial. A total of 377 adult patients in 13 centers were enrolled during the grass pollen season. The primary efficacy variable was the weekly average of the SSI (Symptom Severity Index), the sum of daily nasal congestion, rhinorrhea, and sneezing severity scores from the patient diary. A total of 355 patients completed the study. All active treatments were significantly more effective than placebo in relieving nasal symptoms at each treatment week. The 400 μg Tri-Nasal Nasal Spray and Nasacort treatments had a rapid onset of action, demonstrating significant improvement in the SSI versus placebo by the second day of treatment. Results for the individual nasal symptoms and other secondary efficacy measures paralleled those of the primary efficacy variables. Tri-Nasal Nasal Spray and Nasacort were comparable in safety, and in treating the nonocular symptoms of seasonal allergic rhinitis.

AB - Tri-Nasal Nasal Spray is an investigational solution of triamcinolone acetonide (TAA) currently being evaluated as a treatment for allergic rhinitis. The safety and efficacy of 200 and 400 μg once daily doses of Tri- Nasal Nasal Spray, an active control (440 μg once daily of Nasacort Nasal aerosol), and Tri-Nasal Spray placebo were compared over a 2-week treatment period in a double-blind (the Nasacort treatment was not blinded), parallel design trial. A total of 377 adult patients in 13 centers were enrolled during the grass pollen season. The primary efficacy variable was the weekly average of the SSI (Symptom Severity Index), the sum of daily nasal congestion, rhinorrhea, and sneezing severity scores from the patient diary. A total of 355 patients completed the study. All active treatments were significantly more effective than placebo in relieving nasal symptoms at each treatment week. The 400 μg Tri-Nasal Nasal Spray and Nasacort treatments had a rapid onset of action, demonstrating significant improvement in the SSI versus placebo by the second day of treatment. Results for the individual nasal symptoms and other secondary efficacy measures paralleled those of the primary efficacy variables. Tri-Nasal Nasal Spray and Nasacort were comparable in safety, and in treating the nonocular symptoms of seasonal allergic rhinitis.

UR - http://www.scopus.com/inward/record.url?scp=0032422854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032422854&partnerID=8YFLogxK

M3 - Article

C2 - 9883300

AN - SCOPUS:0032422854

VL - 12

SP - 427

EP - 433

JO - American Journal of Rhinology and Allergy

JF - American Journal of Rhinology and Allergy

SN - 1945-8924

IS - 6

ER -